Breakthrough medicines and biologics have the potential to transform the way we treat some of the most serious and rare diseases, but patient access will be at risk until existing reimbursement policies are updated to reflect the current state of innovation. Novel payment mechanisms that reflect the full value of these transformative therapies, and the promise they bring to seriously ill patients, are needed to sustain this important biomedical progress.